You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Nucala (mepolizumab)

Nucala is now the only anti-IL-5 therapy for severe eosinophilic asthma (SEA) with efficacy and safety demonstrated for up to 4.5 years.1,2 Discover more about its powerful exacerbation and daily OCS reductions. 3-6

Find out more

References:

  1. Albers FC et al. Durability of clinical response following long-term treatment with mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Poster presented at ATS 2018.
  2. Ortega H et al. Long-term safety of mepolizumab in patients with severe eosinophilic asthma: the COLUMBA study. Poster presented at ATS 2018.
  3. Ortega HG et al. N Engl J Med 2014; 371:1198–1207.
  4. Chupp GL et al. Lancet Respir Med 2017; 5:390–400.
  5. Lugogo N et al. Clin Ther 2016; 38:2058–2070.
  6. Bel EH et al. N Engl J Med 2014; 371;1189-1197.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Nucala is a registered trademark of the GlaxoSmithKline Group of Companies

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back